Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors

This publication has 133 references indexed in Scilit:

• Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia
  Cell Death & Differentiation, 2001
• Suppression of poly (ADP‐ribose) polymerase activation by 3‐aminobenzamide in a rat model of myocardial infarction: long‐term morphological and functional consequences
  British Journal of Pharmacology, 2001
• A Bidirectional Promoter Connects the Poly(ADP-ribose) Polymerase 2 (PARP-2) Gene to the Gene for RNase P RNA
  Journal of Biological Chemistry, 2001
• Effects of inhibitors of the activity of poly (ADP‐ribose) synthetase on the liver injury caused by ischaemia‐reperfusion: a comparison with radical scavengers
  British Journal of Pharmacology, 1998
• Protection by Inhibition of Poly (ADP-ribose) Synthetase Against Oxidant Injury in Cardiac MyoblastsIn Vitro
  Journal of Molecular and Cellular Cardiology, 1997
• A survey of telomerase activity in human cancer
  Published by Elsevier ,1997
• Major vault protein LRP-related multidrug resistance
  European Journal Of Cancer, 1996
• Poly(ADP‐Ribose) Synthetase Activation: An Early Indicator of Neurotoxic DNA Damage
  Journal of Neurochemistry, 1995
• Nitric Oxide Toxicity in Islet Cells Involves Poly(ADP-Ribose) Polymerase Activation and Concomitant NAD+ Depletion
  Biochemical and Biophysical Research Communications, 1994
• 3-Aminobenzamide synergistically increases sister-chromatid exchanges in cells exposed to methyl methanesulfonate but not to ultraviolet light
  Mutation Research Letters, 1982